Andy Chen
Stock Analyst at Wolfe Research
(0.89)
# 2265
Out of 5,370 analysts
42
Total ratings
38.46%
Success rate
1.63%
Average return
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma | Initiates Coverage On: Outperform | 49 | 40.72 | 20.33% | 1 | Jun 17, 2025 | |
SRPT Sarepta Therapeutics | Initiates Coverage On: Peer Perform | n/a | n/a | n/a | 1 | Jun 17, 2025 | |
RNA Avidity Biosciences | Initiates Coverage On: Outperform | 55 | 31.08 | 76.96% | 1 | Jun 17, 2025 | |
BPMC Blueprint Medicines | Downgrades: Peer Perform | n/a | n/a | n/a | 1 | Jun 3, 2025 | |
MLTX MoonLake | Upgrades: Outperform | 61 | 42.51 | 43.5% | 3 | May 19, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 21 | 9.89 | 112.34% | 2 | Apr 21, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Peer Perform | n/a | n/a | n/a | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 20 | n/a | n/a | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 49 | 21.54 | 127.48% | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 19 | 10.14 | 87.38% | 1 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 2 | Jan 3, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 697 | 544.81 | 27.93% | 2 | Nov 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | n/a | n/a | n/a | 2 | Nov 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Oct 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 3 | Sep 27, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 65 | 46.66 | 39.31% | 2 | Aug 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 3 | May 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 3 | Apr 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Apr 10, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Peer Perform | n/a | n/a | n/a | 1 | Feb 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 17 | 11.02 | 54.26% | 1 | Feb 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 42 | 101.21 | -58.5% | 1 | Feb 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 60 | n/a | n/a | 1 | Aug 8, 2023 |